Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of DS-1103a combined with trastuzumab deruxtecan in HER2-altered advanced solid tumors
jRCT2031260255Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of DS-1103a and trastuzumab deruxtecan in Nonhematologic neoplasms (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Number of participants with dose-limiting toxicities, Objective response rate by blinded independent central review and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
DS-1103atrastuzumab deruxtecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031260255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260255.